203 related articles for article (PubMed ID: 12584469)
21. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
22. [Skin cancers in kidney transplant recipients].
Bieryło A; Brzósko S; Laudańska E; Naumnik B
Wiad Lek; 2017; 70(1):68-73. PubMed ID: 28343197
[TBL] [Abstract][Full Text] [Related]
23. Cancer incidence after immunosuppressive treatment following kidney transplantation.
Andrés A
Crit Rev Oncol Hematol; 2005 Oct; 56(1):71-85. PubMed ID: 15978827
[TBL] [Abstract][Full Text] [Related]
24. Postrenal transplant malignancy: Incidence, risk factors, and prognosis.
Elserwy NA; Lotfy EE; Fouda MA; Mahmoud MI; Donia AF; Mashaly ME; Abbas MH; Abuelmagd MM; Abouelenein RK; Ismail MI; Bakr MA
Saudi J Kidney Dis Transpl; 2017; 28(3):579-588. PubMed ID: 28540896
[TBL] [Abstract][Full Text] [Related]
25. Incidence and clinical course of de-novo malignancies in renal allograft recipients.
Winkelhorst JT; Brokelman WJ; Tiggeler RG; Wobbes T
Eur J Surg Oncol; 2001 Jun; 27(4):409-13. PubMed ID: 11417989
[TBL] [Abstract][Full Text] [Related]
26. Urothelial carcinoma of donor origin in a kidney transplant patient.
Michel Ortega RM; Wolff DJ; Schandl CA; Drabkin HA
J Immunother Cancer; 2016; 4():63. PubMed ID: 27777772
[TBL] [Abstract][Full Text] [Related]
27. Incidence and consequences of post-transplantation lymphoproliferative disorders.
Boubenider S; Hiesse C; Goupy C; Kriaa F; Marchand S; Charpentier B
J Nephrol; 1997; 10(3):136-45. PubMed ID: 9238621
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A; Campistol JM
Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
[TBL] [Abstract][Full Text] [Related]
29. Transmission of donor melanoma by organ transplantation.
Strauss DC; Thomas JM
Lancet Oncol; 2010 Aug; 11(8):790-6. PubMed ID: 20451456
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
32. Burden of de novo malignancy in the liver transplant recipient.
Chandok N; Watt KD
Liver Transpl; 2012 Nov; 18(11):1277-89. PubMed ID: 22887956
[TBL] [Abstract][Full Text] [Related]
33. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.
Wimmer CD; Rentsch M; Crispin A; Illner WD; Arbogast H; Graeb C; Jauch KW; Guba M
Kidney Int; 2007 Jun; 71(12):1271-8. PubMed ID: 17332737
[TBL] [Abstract][Full Text] [Related]
34. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
35. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
[TBL] [Abstract][Full Text] [Related]
36. Post-transplantation Malignancy After Kidney Transplantation in Turkey.
Keles Y; Tekin S; Duzenli M; Yuksel Y; Yücetin L; Dosemeci L; Sengul A; Demirbaş A; Tuncer M
Transplant Proc; 2015 Jun; 47(5):1418-20. PubMed ID: 26093732
[TBL] [Abstract][Full Text] [Related]
37. [Skin lesions in renal transplant recipients].
Myśliwiec H; Chodynicka B; Serwin AB
Wiad Lek; 2002; 55(3-4):214-20. PubMed ID: 12182007
[TBL] [Abstract][Full Text] [Related]
38. [Malignant neoplasias in renal transplantation recipients].
Gómez-Roel X; León-Rodríguez E
Rev Invest Clin; 2005; 57(2):225-9. PubMed ID: 16524062
[TBL] [Abstract][Full Text] [Related]
39. Management of the kidney transplant recipient.
Padiyar A; Akoum FH; Hricik DE
Prim Care; 2008 Sep; 35(3):433-50, v. PubMed ID: 18710663
[TBL] [Abstract][Full Text] [Related]
40. De Novo Malignant Neoplasms in Renal Transplant Patients.
Yılmaz Akçay E; Tepeoğlu M; Özdemir BH; Deniz E; Börcek P; Haberal M
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):100-105. PubMed ID: 27805524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
